Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Shineway Pharmaceutical Group Limited (2877.HK)
HKD8.29
+0.18 (+2.22%)
CN HKSE Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 168 Shiluan Street 51430
Shijiazhuang, CN
Shijiazhuang, CN
CEO
Zhenjiang Li
Website
shineway.com
IPO
2004-12-02
ISIN KYG2110P1000
Also trades on
Hong Kong Stock Exchange · 2877.HK (HKD)
Other OTC · CSWYF (USD)
Other OTC · CSWYY (USD)
Description
As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product range includes modern Chinese pharmaceuticals delivered as soft capsules, granular preparations, and injectable forms, alongside specialized Traditional Chinese Medicine (TCM) Formula Granules. These offerings cater to a broad spectrum of therapeutic needs, such as cardiovascular and cerebrovascular health, anti-viral applications, orthopedic conditions, pediatric ailments, gynecological care, and gastrointestinal issues. Furthermore, the company is involved in the trading of agricultural commodities. Founded in 2004, its headquarters are situated in Shijiazhuang, PRC, and it functions as a subsidiary of Forway Investment Limited.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD8.29
+0.18 (+2.22%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.71
Float Shares
254.51M
Free Float %
33.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.07% | +0.96% | -13.70% | -10.85% | -4.45% | -2.56% | +9.97% | -4.88% | -0.71% | +1.82% | +72.78% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
8.29
DCF (Unlevered)
22.55
+172.0%
DCF (Levered)
25.56
+208.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.05
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A+
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-17.0% Q4'25: -30.0% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+13.5% Q4'25: -30.2% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+27.4% Q4'25: +40.1% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+21.8% ★ Q4'25: +21.0% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+61.4% ★ Q4'25: +101.5% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.45× ★ Q4'25: 0.28× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.63B
est: 1.42B (+14.8%)
|
2.04B
est: 1.79B (+13.9%)
|
1.98B
est: 1.81B (+9.6%)
|
2.13B
est: 1.73B (+23.6%)
|
2.19B
est: 1.85B (+18.2%)
|
2.23B
est: 1.85B (+20.5%)
|
2.05B
est: 2.63B (-22.0%)
|
1.99B
est: 2.06B (-3.3%)
|
1.92B
est: 2.22B (-13.5%)
|
2.57B
est: 2.92B (-12.0%)
|
2.71B
est: 3.14B (-13.7%)
|
2.66B
est: 3.18B (-16.6%)
|
3.22B
est: 4.01B (-19.5%)
|
3.95B
est: 4.35B (-9.2%)
|
4.52B
est: 3.91B (+15.5%)
|
3.78B
est: 4.41B (-14.4%)
|
3.14B
est: 3.84B (-18.3%)
|
3.15B
3.15B – 3.15B
-18.0% YoY
|
3.38B
3.38B – 3.38B
+7.5% YoY
|
3.64B
3.64B – 3.64B
+7.7% YoY
|
| EBITDA |
883.20M
est: 551.76M (+60.1%)
|
1.04B
est: 1.04B (+0.9%)
|
1.02B
est: 883.27M (+14.9%)
|
757.45M
est: 790.30M (-4.2%)
|
788.03M
est: 763.66M (+3.2%)
|
844.85M
est: 752.24M (+12.3%)
|
776.63M
est: 814.57M (-4.7%)
|
778.67M
est: 691.97M (+12.5%)
|
602.71M
est: 761.54M (-20.9%)
|
691.76M
est: 948.70M (-27.1%)
|
850.41M
est: 829.47M (+2.5%)
|
620.04M
est: 684.61M (-9.4%)
|
903.74M
est: 731.55M (+23.5%)
|
1.10B
est: 789.36M (+39.8%)
|
1.42B
est: 1.08B (+32.0%)
|
1.00B
est: 1.21B (-17.4%)
|
739.53M
est: 1.06B (-29.9%)
|
865.42M
865.42M – 865.42M
-18.0% YoY
|
930.74M
930.74M – 930.74M
+7.5% YoY
|
1.00B
1.00B – 1.00B
+7.7% YoY
|
| EBIT |
712.52M
est: 512.98M (+38.9%)
|
991.81M
est: 985.37M (+0.7%)
|
880.53M
est: 838.39M (+5.0%)
|
799.74M
est: 739.23M (+8.2%)
|
862.93M
est: 694.90M (+24.2%)
|
880.60M
est: 678.39M (+29.8%)
|
797.23M
est: 711.52M (+12.0%)
|
583.55M
est: 574.80M (+1.5%)
|
408.07M
est: 597.39M (-31.7%)
|
669.13M
est: 712.70M (-6.1%)
|
645.43M
est: 640.46M (+0.8%)
|
411.62M
est: 522.86M (-21.3%)
|
721.36M
est: 558.71M (+29.1%)
|
917.66M
est: 602.87M (+52.2%)
|
1.24B
est: 915.25M (+35.8%)
|
835.99M
est: 1.03B (-19.0%)
|
682.07M
est: 898.09M (-24.1%)
|
736.37M
736.37M – 736.37M
-18.0% YoY
|
791.95M
791.95M – 791.95M
+7.5% YoY
|
852.62M
852.62M – 852.62M
+7.7% YoY
|
| Net Income |
767.30M
est: 428.95M (+78.9%)
|
821.76M
est: 855.29M (-3.9%)
|
755.60M
est: 694.68M (+8.8%)
|
647.70M
est: 588.27M (+10.1%)
|
683.65M
est: 563.03M (+21.4%)
|
704.78M
est: 538.18M (+31.0%)
|
657.91M
est: 569.45M (+15.5%)
|
589.20M
est: 474.35M (+24.2%)
|
451.55M
est: 506.26M (-10.8%)
|
505.88M
est: 547.48M (-7.6%)
|
503.15M
est: 484.20M (+3.9%)
|
295.03M
est: 407.60M (-27.6%)
|
556.67M
est: 435.55M (+27.8%)
|
722.77M
est: 883.12M (-18.2%)
|
969.51M
est: 1.03B (-5.6%)
|
840.05M
est: 921.25M (-8.8%)
|
949.95M
est: 770.19M (+23.3%)
|
991.06M
991.06M – 991.06M
+28.7% YoY
|
1.11B
1.11B – 1.11B
+12.2% YoY
|
1.23B
1.23B – 1.23B
+10.4% YoY
|
| SGA |
489.27M
est: 390.17M (+25.4%)
|
546.80M
est: 545.41M (+0.3%)
|
484.64M
est: 462.22M (+4.9%)
|
676.02M
est: 377.28M (+79.2%)
|
701.16M
est: 587.63M (+19.3%)
|
697.06M
est: 552.04M (+26.3%)
|
677.80M
est: 563.22M (+20.3%)
|
648.30M
est: 488.69M (+32.7%)
|
762.51M
est: 557.04M (+36.9%)
|
1.25B
est: 924.50M (+35.6%)
|
1.40B
est: 1.20B (+16.9%)
|
1.47B
est: 1.14B (+29.0%)
|
1.76B
est: 1.21B (+45.2%)
|
2.11B
est: 1.31B (+60.9%)
|
2.31B
est: 2.00B (+15.6%)
|
1.89B
est: 2.25B (-16.1%)
|
1.45B
est: 1.96B (-26.2%)
|
1.61B
1.61B – 1.61B
-18.0% YoY
|
1.73B
1.73B – 1.73B
+7.5% YoY
|
1.86B
1.86B – 1.86B
+7.7% YoY
|
| EPS |
0.93
est: 0.78 (+19.4%)
|
0.99
est: 0.84 (+17.2%)
|
0.91
est: 0.81 (+12.7%)
|
0.78
est: 0.70 (+12.1%)
|
0.83
est: 0.71 (+16.7%)
|
0.85
est: 0.72 (+17.7%)
|
0.80
est: 0.93 (-14.1%)
|
0.71
est: 0.68 (+4.4%)
|
0.55
est: 0.58 (-5.5%)
|
0.62
est: 0.74 (-16.4%)
|
0.64
est: 0.81 (-20.5%)
|
0.39
est: 0.62 (-36.7%)
|
0.74
est: 1.15 (-35.9%)
|
0.96
est: 1.00 (-3.9%)
|
1.28
est: 1.36 (-5.9%)
|
1.11
est: 1.22 (-9.0%)
|
1.26
est: 1.02 (+23.6%)
|
1.31
1.31 – 1.31
+28.7% YoY
|
1.47
1.47 – 1.47
+12.2% YoY
|
1.63
1.63 – 1.63
+10.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-12 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-11 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-07 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-06 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-05 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-04 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.30B
OE per share TTM
1.72
Owner's Yield
20.57%
Maintenance CapEx ratio
100.47%
Maint CapEx / Avg PPE
37.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 53 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.20% | 132.6K | 0.59% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 233.1K | 0.65% |
| 3 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.03% | 39.2K | 0.42% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.03% | 19.6K | 0.74% |
| 5 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 97.7K | 0.72% |
| 6 | State Street SPDR S&P China ETF GXC | 0.03% | 115.0K | 0.59% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 140.8K | 0.55% |
| 8 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 52.7K | 0.74% |
| 9 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.01% | 24.5K | 0.33% |
| 10 | Avantis Emerging Markets Value ETF AVES | 0.01% | 118.6K | 0.36% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
211.8K
Shares Outstanding
755.40M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhenjiang Li | Co-Founder & Executive Chairman | 9M | male |
| Yunxia Xin | Co-Founder & Executive Director | 4M | female |
| Huimin Li | Executive Director | 2M | male |
| King Kuen Hung | Director of Investor Relation | 38.1K | male |
| Bun Ching Lee | Financial Controller & Company Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2877.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
